Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Open Label, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of CM-101 Administered for 12 Weeks in Adult Subjects with Primary Sclerosing Cholangitis

Trial Profile

A Phase 2, Open Label, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of CM-101 Administered for 12 Weeks in Adult Subjects with Primary Sclerosing Cholangitis

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nebokitug (Primary)
  • Indications Primary sclerosing cholangitis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms SPRING
  • Sponsors Chemomab Therapeutics

Most Recent Events

  • 30 Jun 2025 According to a Chemomab Therapeutics media release, rececent findings from this Phase 2 SPRING trial suggest that nebokitug may have disease-modifying potential in PSC and support advancement to a Phase 3 registration trial.
  • 30 Jun 2025 Results published in the Media Release
  • 30 Jun 2025 According to a Chemomab Therapeutics media release, company announced that data from the company's Phase 2 SPRING trial of nebokitug (CM-101) in patients with primary sclerosing cholangitis (PSC) was presented in an oral session1 at BSG Live 25, the annual scientific meeting of the British Society for Gastroenterology, in Glasgow, UK.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top